{
    "clinical_study": {
        "@rank": "85541", 
        "arm_group": [
            {
                "arm_group_label": "Bright White Light (BWL)", 
                "arm_group_type": "Experimental", 
                "description": "Participants will self-administer bright white light daily using a Litebook\u00ae (The Litebook Company Ltd.). The Litebook is a small (6\" x 5\" x 1\") and lightweight (8 oz.) box."
            }, 
            {
                "arm_group_label": "Dim Red Light (DRL)", 
                "arm_group_type": "Active Comparator", 
                "description": "Participants will self-administer dim red light daily using a device that appears identical to Bright White Light (BWL) Litebook but that uses red LEDs emitting DRL."
            }
        ], 
        "brief_summary": {
            "textblock": "This study aims to evaluate the efficacy of 4 weeks of daily light exposure in reducing\n      Post-Traumatic Brain Injury (TBI) Fatigue immediately post-treatment and at a one-month\n      follow up. The investigators hypothesize that individuals receiving 4 weeks of bright white\n      light treatment will report significant reductions in fatigue compared to individuals\n      receiving dim red light treatment for the same duration of time, and that these treatment\n      effects will be maintained one month after treatment completion."
        }, 
        "brief_title": "Treatment of Post-Traumatic Brain Injury (Post-TBI) Fatigue With Light Therapy", 
        "completion_date": {
            "#text": "September 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Traumatic Brain Injury", 
            "Fatigue"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Fatigue", 
                "Brain Injuries", 
                "Wounds and Injuries"
            ]
        }, 
        "detailed_description": {
            "textblock": "To determine the efficacy of bright white light exposure compared to dim red light exposure\n      in reducing post-TBI fatigue, an 8-week, randomized parallel-group clinical trial will be\n      performed. Outcome assessment will be blinded. Participants will complete a baseline battery\n      (T1) including 72 hours of actigraphy. Participants will then be randomized to either the\n      Bright White Light (BWL) or the Dim Red Light (DRL) group. After 4 weeks of daily, 30-minute\n      light treatments, the baseline battery will be re-administered (T2) along with 3 more days\n      of Actigraphy. A follow-up assessment involving the same measures will be administered 1\n      month-post cessation of light therapy (T3). Participant treatment allocations will be masked\n      for research team members conducting outcome measures. Secondary outcome measures will be\n      administered to explore the effects of light therapy on mood, daytime sleepiness, sleep\n      quality, circadian rhythms, anxiety, cognition and life satisfaction."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Documented TBI of any severity\n\n          -  At least 12 months post injury\n\n          -  Presence of clinically significant fatigue, operationalized as a score of 22 or more\n             on the Multidimensional Assessment of Fatigue\n\n          -  Age 18 or older\n\n          -  English speaking\n\n        Exclusion Criteria:\n\n          -  Neurological disease other than TBI\n\n          -  Pregnancy (because of pregnancy fatigue)\n\n          -  Medical illness causing fatigue, such as anemia, hypothyroidism, HIV, renal failure,\n             cirrhosis or cancer treatment in the past year\n\n          -  Current major depressive episode or substance abuse\n\n          -  Diagnosed sleep disorder or high risk for sleep apnea\n\n          -  History of bipolar disorder or manic or hypomanic episodes\n\n          -  Current chronic, severe headaches\n\n          -  Sensitivity to bright light\n\n          -  History of retinal damage or disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "95", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01725750", 
            "org_study_id": "GCO 12-1256", 
            "secondary_id": [
                "HSM 12-00759", 
                "H133A120084"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Bright White Light (BWL)", 
                "description": "Participants will self-administer bright white light daily. Litebooks used for Bright White Light and Dim Red Light are identical except for the light which they emit. Users are instructed to place it about 18\" from their face and within 45\u00ba of the visual field for 30 minutes within half an hour of waking each morning, for 4 weeks. The participant may eat, read, watch TV, etc. while sitting in front of the box.", 
                "intervention_name": "Bright White Light (BWL)", 
                "intervention_type": "Device", 
                "other_name": "Litebook - Bright White Light"
            }, 
            {
                "arm_group_label": "Dim Red Light (DRL)", 
                "description": "A device that appears identical to BWL Litebook but that uses red LEDs emitting DRL.  Users are instructed to place it about 18\" from their face and within 45\u00ba of the visual field for 30 minutes within half an hour of waking each morning, for 4 weeks. The participant may eat, read, watch TV, etc. while sitting in front of the box.", 
                "intervention_name": "Dim Red Light (DRL)", 
                "intervention_type": "Device", 
                "other_name": "Litebook - Dim Red Light"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Traumatic Brain Injury", 
            "TBI", 
            "Fatigue", 
            "Post-TBI Fatigue", 
            "PTBIF", 
            "Depressed Mood", 
            "Excessive Daytime Sleepiness", 
            "Circadian Rhythm", 
            "Anxiety", 
            "Cognitive Dysfunction", 
            "Intervention", 
            "Treatment"
        ], 
        "lastchanged_date": "September 24, 2013", 
        "location": {
            "contact": {
                "email": "jason.krellman@mountsinai.org", 
                "last_name": "Jason Krellman, PhD"
            }, 
            "contact_backup": {
                "email": "Wayne.Gordon@mountsinai.org", 
                "last_name": "Wayne Gordon, PhD", 
                "phone": "212-659-9372"
            }, 
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10029"
                }, 
                "name": "The Brain Injury Research Center at Icahn School of Medicine at Mount Sinai"
            }, 
            "investigator": {
                "last_name": "Wayne Gordon, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Treatment of Post-TBI Fatigue With Light Therapy", 
        "overall_contact": {
            "email": "jason.krellman@mountsinai.org", 
            "last_name": "Jason Krellman, PhD"
        }, 
        "overall_official": {
            "affiliation": "Mount Sinai School of Medicine", 
            "last_name": "Wayne Gordon, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Multidimensional Assessment of Fatigue (MAF) yields a Global Fatigue Index (GFI), assessing 5 dimensions of fatigue: distress, degree, severity, impact on ADLs and frequency of fatigue in the past week, and it yields a composite score.", 
                "measure": "Multidimensional Assessment of Fatigue (MAF)", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "description": "See above", 
                "measure": "Multidimensional Assessment of Fatigue (MAF)", 
                "safety_issue": "No", 
                "time_frame": "at 4 weeks (end-of-treatment)"
            }, 
            {
                "description": "See above", 
                "measure": "Multidimensional Assessment of Fatigue (MAF)", 
                "safety_issue": "No", 
                "time_frame": "one month post treatment"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01725750"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mount Sinai School of Medicine", 
            "investigator_full_name": "Wayne Gordon", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The TBI-QOL Fatigue measure will be used. TBI-QOL measures form part of the Promis Neuro-QOL initiative and include well-validated self-report measures that assess the health-related QOL of individuals with neurological disorders.", 
                "measure": "TBI-QOL Fatigue", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "description": "See above", 
                "measure": "TBI-QOL Fatigue", 
                "safety_issue": "No", 
                "time_frame": "at 4 weeks (end-of-treatment)"
            }, 
            {
                "description": "See above", 
                "measure": "TBI-QOL Fatigue", 
                "safety_issue": "No", 
                "time_frame": "one month post treatment"
            }, 
            {
                "description": "The Neuro-QOL Depression and Sleep measures will be used", 
                "measure": "Neuro-QOL Depression and Sleep", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "description": "The Neuro-QOL Depression and Sleep measures will be used", 
                "measure": "Neuro-QOL Depression and Sleep", 
                "safety_issue": "No", 
                "time_frame": "at 4 weeks (end-of-treatment)"
            }, 
            {
                "description": "The Neuro-QOL Depression and Sleep measures will be used", 
                "measure": "Neuro-QOL Depression and Sleep", 
                "safety_issue": "No", 
                "time_frame": "one month post treatment"
            }, 
            {
                "description": "The Epworth Sleepiness Scale (ESS) will also be used, to assess daytime sleepiness; it is an 8-item measure that asks about the probability of dozing or sleeping during typical daytime activities and has been widely used in TBI research. Scores correlate well with objective measures of speed of daytime sleep onset.", 
                "measure": "Epworth Sleepiness Scale (ESS)", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "description": "See above", 
                "measure": "Epworth Sleepiness Scale (ESS)", 
                "safety_issue": "No", 
                "time_frame": "at 4 weeks (end-of-treatment)"
            }, 
            {
                "description": "See above", 
                "measure": "Epworth Sleepiness Scale (ESS)", 
                "safety_issue": "No", 
                "time_frame": "one month post treatment"
            }, 
            {
                "description": "The CNS Vital Signs TBI Rehab Toolbox is a brief, 25-minute computerized cognition battery; it emphasizes those cognitive functions that are the most likely to respond to alerting effects of light (vigilance, attention, speed) and has multiple forms for serial assessment.", 
                "measure": "CNS Vital Signs TBI Rehab Toolbox", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "description": "See above", 
                "measure": "CNS Vital Signs TBI Rehab Toolbox", 
                "safety_issue": "No", 
                "time_frame": "at 4 weeks (end-of-treatment)"
            }, 
            {
                "description": "See above", 
                "measure": "CNS Vital Signs TBI Rehab Toolbox", 
                "safety_issue": "No", 
                "time_frame": "one month post treatment"
            }, 
            {
                "description": "The Cognitive Failures Questionnaire (CFQ)100 is a 25-item self-report inventory, with items measuring difficulties in several cognitive domains (e.g., memory, perception).", 
                "measure": "Cognitive Failures Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "description": "See above", 
                "measure": "Cognitive Failures Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "at 4 weeks (end-of-treatment)"
            }, 
            {
                "description": "See above", 
                "measure": "Cognitive Failures Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "one month post treatment"
            }, 
            {
                "description": "The Neuro-QOL Anxiety measure will be used", 
                "measure": "Neuro-QOL Anxiety", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "description": "The Neuro-QOL Anxiety measure will be used", 
                "measure": "Neuro-QOL Anxiety", 
                "safety_issue": "No", 
                "time_frame": "at 4 weeks (end-of-treatment)"
            }, 
            {
                "description": "The Neuro-QOL Anxiety measure will be used", 
                "measure": "Neuro-QOL Anxiety", 
                "safety_issue": "No", 
                "time_frame": "one month post treatment"
            }, 
            {
                "description": "Philips Actiwatch Spectrum to measure circadian rhythms; it is the size and shape of a digital wristwatch and weighs about one ounce. It is worn on an ordinary watchband and is waterproof. Data can be downloaded and analyzed using Actiware software. The Actiwatch Spectrum logs all physical movement using a piezoelectric accelerometer and detects the presence of ambient light (400-700nm), making it a useful measure of circadian cycles because it allows for accurate quantitative assessment of periods of activity, rest and sleep.", 
                "measure": "Actiwatch Spectrum", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "description": "See above", 
                "measure": "Actiwatch Spectrum", 
                "safety_issue": "No", 
                "time_frame": "at 4 weeks (end-of-treatment)"
            }, 
            {
                "description": "Satisfaction with Life Scale, a 5-item measure of global satisfaction with life.", 
                "measure": "Satisfaction with Life Scale", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "description": "Satisfaction with Life Scale, a 5-item measure of global satisfaction with life.", 
                "measure": "Satisfaction with Life Scale", 
                "safety_issue": "No", 
                "time_frame": "at 4 weeks (end-of-treatment)"
            }, 
            {
                "description": "Satisfaction with Life Scale, a 5-item measure of global satisfaction with life.", 
                "measure": "Satisfaction with Life Scale", 
                "safety_issue": "No", 
                "time_frame": "one month post treatment"
            }, 
            {
                "description": "An adapted version of the Treatment Satisfaction Questionnaire for Medication. This is a validated, psychometrically sound measure of general treatment satisfaction.", 
                "measure": "Treatment Satisfaction Questionnaire for Medication", 
                "safety_issue": "No", 
                "time_frame": "at 4 weeks (end-of-treatment)"
            }, 
            {
                "description": "See above", 
                "measure": "Treatment Satisfaction Questionnaire for Medication", 
                "safety_issue": "No", 
                "time_frame": "one month post treatment"
            }, 
            {
                "description": "Assess treatment credibility (BWL vs. DRL) with the Credibility/Expectancy Questionnaire, used in clinical outcome studies", 
                "measure": "Credibility/Expectancy Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "at 4 weeks (end-of-treatment)"
            }, 
            {
                "description": "Assess treatment credibility (BWL vs. DRL) with the Credibility/Expectancy Questionnaire, used in clinical outcome studies", 
                "measure": "Credibility/Expectancy Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "one month post treatment"
            }
        ], 
        "source": "Mount Sinai School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mount Sinai School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}